UpSwinG: Real World study on TKI activity in Uncommon mutations and Sequencing Giotrif®

Study identification

• EU PAS number:
  EUPAS32098
• Study ID:
  32099
• Official title and acronym:
  UpSwinG: Real World study on TKI activity in Uncommon mutations and Sequencing Giotrif®
• DARWIN EU® study:
  No
• Study countries:
  Austria

  China

  France

  Germany

  Italy

  Japan

  Korea, Republic of

  Spain

  Taiwan

  United Kingdom
• Study description:
  This is a non-interventional, multi-country, multi-centre study based on existing data from medical records or electronic health records.The study observes how long patients with non-small cell lung cancer (NSCLC) benefit from treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) when given either for uncommon mutations or for common mutations in the sequence afatinib followed by osimertinib. Total enrolled: at least 200 patients per cohortFor both cohorts the study aims to describe the time on treatment until its end or death.
• Study status:
  Planned

Research institutions and networks

Institutions

Royal Marsden Hospital

Study timelines

Date when funding contract was signed

Planned:06/12/2019

Study start date

Planned:09/12/2019

Data analysis start date

Planned:01/12/2020

Date of final study report

Planned:31/12/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim International

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable